Yellow Fever – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Yellow Fever – Drugs In Development, 2024 report and make more profitable business decisions.
Yellow fever is an acute systemic illness (hemorrhagic fever) caused by a flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeat, bleeding, vomiting, coma, delirium, fever, headache, and muscle aches. There is no specific treatment for yellow fever, so patients are treated to relieve the symptoms.
The Yellow Fever drugs in development market research report provide comprehensive information on the therapeutics under development for Yellow Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Yellow Fever | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Yellow Fever therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Yellow Fever pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Yellow Fever treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aix-Marseille UniversityAstriVax NV
Bavarian Nordic AS
Biological E Ltd
China National Pharmaceutical Group Corp
Codagenix Inc
Collaborations Pharmaceuticals Inc
Curevac NV
Dultech Advanced Sciences
Emergex Vaccines Holding Ltd
Ennaid Therapeutics LLC
iBio Inc
Imutex Ltd
Inventprise LLC
Mabloc LLC
Medigen Inc
Najit Technologies Inc
Saint Louis University
Sanofi
Serum Institute of India Pvt Ltd
SmartBioTech
Theravectys SA
Tychan Pte Ltd
Universal Stabilization Technologies Inc
University of Queensland
Vernagen Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Yellow Fever reports